Manipulation of the nerve growth factor network in prostate cancer

Bibliography

• BOLLA M, VAN POPPEL H, COLLETTE L et al.: Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet (2005) 366(9485):572-578.
   PubMed Web of Science ®Google Scholar
• WIEGEL T, BOTTKE D, WILLICH N et al.: Phase III results in adjuvant radiotherapy versus wait and see in patients with pT3 prostate cancer following radical prostatectomy. Proc. Am. Clin. Oncol. USA (2005) 23:4513.
   Google Scholar
• PAPATSORIS AG, PAPAVASSILIOU AG: Prostate cancer: horizons in the development of novel anti-cancer strategies. Curr. Med. Chem. Anticancer Agents (2001) 1(1):47-70.
   PubMedGoogle Scholar
• PAPATSORIS AG, KARAMOUZIS MV, PAPAVASSILIOU AG: Novel biological agents for the treatment of hormone-refractory prostate cancer (HRPC). Curr. Med. Chem. (2005) 12(3):277-296.
   PubMed Web of Science ®Google Scholar
• PAPATSORIS AG, KARAMOUZIS MV, PAPAVASILLIOU AG: Novel insights into the implication of the IGF-1 network in prostate cancer. Trends Mol. Med. (2005) 11(2):52-55.
   PubMed Web of Science ®Google Scholar
• NELSON WG: Agents in development for prostate cancer prevention. Expert Opin. Investig. Drugs (2004) 13(12):1541-1554.
   PubMed Web of Science ®Google Scholar
• LEWIN GR, BARDE YA: Physiology of the neurotrophins. Ann. Rev. Neurosci. (1996) 19:289-317.
   PubMed Web of Science ®Google Scholar
• LI C, WATANABE G, WENG Q et al.: Expression of nerve growth factor (NGF), and its receptors TrkA and p75 in the reproductive organs of the adult male rats. Zoolog. Sci. (2005) 22(8):933-937.
   PubMed Web of Science ®Google Scholar
• AYER-LELIEVRE C, OLSON L, EBENDAL T, HALLBOOK F, PERSSON H: Nerve growth factor mRNA and protein in the testis and epididymis of mouse and rat. Proc. Natl. Acad. Sci. USA (1988) 85(8):2628-2632.
   PubMed Web of Science ®Google Scholar
• SEIDL K, HOLSTEIN AF: Evidence for the presence of nerve growth factor (NGF) and NGF receptors in human testis. Cell Tissue Res. (1990) 261(3):549-554.
   PubMed Web of Science ®Google Scholar
• GRAHAM CW, LYNCH JH, DJAKIEW D: Distribution of nerve growth factor-like protein and nerve growth factor receptor in human benign prostatic hyperplasia and prostatic adenocarcinoma. J. Urol. (1992) 147(5):1444-1447.
   PubMed Web of Science ®Google Scholar
• SORTINO MA, CONDORELLI F, VANCHERI C et al.: Mitogenic effect of nerve growth factor (NGF) in LNCaP prostate adenocarcinoma cells: role of the high- and low-affinity NGF receptors. Mol. Endocrinol. (2002) 14(1):124-136.
   Web of Science ®Google Scholar
• DJAKIEW D: Dysregulated expression of growth factors and their receptors in the development of prostate cancer. Prostate (2000) 42(2):150-160.
   PubMed Web of Science ®Google Scholar
• CHUNG LW, LI W, GLEAVE ME et al.: Human prostate cancer model: roles of growth factors and extracellular matrices. J. Cell. Biochem. (1992) 16(Suppl):99-105.
   Google Scholar
• DJAKIEW D, DELSITE R, PFLUG B, WRATHALL J, LYNCH JH, ONODA M: Regulation of growth by a nerve growth factor-like protein which modulates paracrine interactions between a neoplastic epithelial cell line and stromal cells of the human prostate. Cancer Res. (1991) 51(12):3304-3310.
   PubMed Web of Science ®Google Scholar
• CHAO MV: The p75 neurotrophin receptor. J. Neurobiol. (1994) 25(11):1373-1385.
   PubMedGoogle Scholar
• PFLUG B, DJAKIEW D: Expression of p75NTR in a human prostate epithelial tumor cell line reduces nerve growth factor-induced cell growth by activation of programmed cell death. Mol. Carcinog. (1998) 23(2):106-114.
   PubMed Web of Science ®Google Scholar
• KHWAJA F, TABASSUM A, ALLEN J, DJAKIEW D: The p75NTR tumor suppressor induces cell cycle arrest facilitating caspase mediated apoptosis in prostate tumor cells. Biochem. Biophys. Res. Commun. (2006) 341(4):1184-1192.
   PubMed Web of Science ®Google Scholar
• ALLEN J, KHWAJA F, BYERS S, DJAKIEW D: The p75NTR mediates a bifurcated signal transduction cascade through the NFκB and JNK pathways to inhibit cell survival. Exp. Cell. Res. (2005) 304(1):69-80.
   PubMed Web of Science ®Google Scholar
• PFLUG BR, ONODA M, LYNCH JH, DJAKIEW D: Reduced expression of the low affinity nerve growth factor receptor in benign and malignant human prostate tissue and loss of expression in four human metastatic prostate tumor cell lines. Cancer Res. (1992) 52(19):5403-5406.
   PubMed Web of Science ®Google Scholar
• PAUL A, HABIB F: Low-affinity nerve growth factor receptors (p75LNGFR) in human prostate tissue: stromal localisation. Urol. Res. (1998) 26(2):111-116.
   PubMed Web of Science ®Google Scholar
• KRYGIER S, DJAKIEW D: Molecular characterization of the loss of p75NTR expression in human prostate tumor cells. Mol. Carcinog. (2001) 31(1):46-55.
   PubMed Web of Science ®Google Scholar
• KRYGIER S, DJAKIEW D: Neurotrophin receptor p75NTR suppresses growth and nerve growth factor-mediated metastasis of human prostate cancer cells. Int. J. Cancer (2002) 98(1):1-7.
   PubMed Web of Science ®Google Scholar
• KRYGIER S, DJAKIEW D: The neurotrophin receptor p75NTR is a tumor suppressor in human prostate cancer. Anticancer Res. (2001) 21(6):3749-3755.
   PubMed Web of Science ®Google Scholar
• MURAKAMI YS, BROTHMAN AR, LEACH RJ, WHITE RL: Suppression of malignant phenotype in a human prostate cancer cell line by fragments of normal chromosomal region 17q. Cancer Res. (1995) 55(15):3389-3394.
   PubMed Web of Science ®Google Scholar
• NALBANDIAN A, DJAKIEW D: The p75NTR metastasis suppressor inhibits urokinase plasminogen activator, matrix metalloproteinase-2 and matrix metalloproteinase-9 in PC-3 prostate cancer cells. Clin. Exp. Metastasis (2006) 23(2):107-116.
   PubMed Web of Science ®Google Scholar
• CHAO MV, HEMPSTEAD BL: p75 and Trk: a two-receptor system. Trends Neurosci. (1995) 18(7):321-326.
   PubMed Web of Science ®Google Scholar
• MAHADEO D, KAPLAN L, CHAO MV, HEMPSTEAD BL: High affinity nerve growth factor binding displays a faster rate of association than p140trk binding. Implications for multi-subunit polypeptide receptors. J. Biol. Chem. (1994) 269(9):6884-6891.
   PubMed Web of Science ®Google Scholar
• MACGROGAN D, SAINT-ANDRE JP, DICOU E: Expression of nerve growth factor and nerve growth factor receptor genes in human tissues and in prostatic adenocarcinoma cell lines. J. Neurochem. (1992) 59(4):1381-1391.
   PubMed Web of Science ®Google Scholar
• DELSITE R, DJAKIEW D: Anti-proliferative effect of the kinase inhibitor K252a on human prostatic carcinoma cell lines. J. Androl. (1996) 17(5):481-490.
   PubMed Web of Science ®Google Scholar
• DALAL R, DJAKIEW D: Molecular characterization of neurotrophin expression and the corresponding tropomyosin receptor kinases (trks) in epithelial and stromal cells of the human prostate. Mol. Cell. Endocrinol. (1997) 134(1):15-22.
   PubMed Web of Science ®Google Scholar
• HARRIS KA, SMALL EJ: Hormonal treatment for prostate cancer. Expert Opin. Investig. Drugs (2001) 10(2):493-510.
   PubMed Web of Science ®Google Scholar
• SANCHEZ C, CLEMENTI M, BENITEZ D, CONTRERAS H, HUIDOBRO C, CASTELLON E: Effect of GnRH analogs on the expression of TrkA and p75 neurotrophin receptors in primary cell cultures from human prostate adenocarcinoma. Prostate (2005) 65(3):195-202.
   PubMed Web of Science ®Google Scholar
• HALVORSON KG, KUBOTA K, SEVCIK MA et al.: A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone. Cancer Res. (2005) 65(20):9426-9435.
   PubMed Web of Science ®Google Scholar
• POMERANTZ M, KANTOFF P: Advances in the treatment of prostate cancer. Ann. Rev. Med. (2006) 58:205-220.
   Web of Science ®Google Scholar
• KANDEL ER, SCHWARTZ JH, JESSELL TM: Principles of neural science. McGraw-Hill, New York, USA (2000):472-479.
   Google Scholar
• SEVCIK MA, GHILARDI JR, PETERS CM et al.: Anti-NGF therapy profoundly reduces bone cancer pain and the accompanying increase in markers of peripheral and central sensitization. Pain (2005) 115(1-2):128-141.
   PubMed Web of Science ®Google Scholar
• SIGALA S, TOGNAZZI N, RIZZETTI MC et al.: Nerve growth factor induces the re-expression of functional androgen receptors and p75(NGFR) in the androgen-insensitive prostate cancer cell line DU145. Eur. J. Endocrinol. (2002) 147(3):407-415.
   PubMed Web of Science ®Google Scholar
• SIGALA S, FARAONI I, BOTTICINI D et al.: Suppression of telomerase, reexpression of KAI1, and abrogation of tumorigenicity by nerve growth factor in prostate cancer cell lines. Clin. Cancer Res. (1999) 5(5):1211-1218.
   PubMed Web of Science ®Google Scholar
• ALLEN J, KHWAJA F, DJAKIEW D: Gene therapy of prostate xenograft tumors with a p75NTR lipoplex. Anticancer Res. (2004) 24(5A):2997-3003.
   PubMed Web of Science ®Google Scholar
• NALBANDIAN A, PANG AL, RENNERT OM, CHAN WY, RAVINDRANATH N, DJAKIEW D: A novel function of differentiation revealed by cDNA microarray profiling of p75NTR-regulated gene expression. Differentiation (2005) 73(8):385-396.
   PubMed Web of Science ®Google Scholar
• FRIEDMAN WJ, GREENE LA: Neurotrophin signaling via Trks and p75. Exp. Cell Res. (1999) 253(1):131-142.
   PubMed Web of Science ®Google Scholar
• WEERARATNA AT, ARNOLD JT, GEORGE DJ, DEMARZO A, ISAACS JT: Rational basis for Trk inhibition therapy for prostate cancer. Prostate (2000) 45(2):140-148.
   PubMed Web of Science ®Google Scholar
• WEERARATNA AT, DALRYMPLE SL, LAMB JC et al.: Pan-trk inhibition decreases metastasis and enhances host survival in experimental models as a result of its selective induction of apoptosis of prostate cancer cells. Clin. Cancer Res. (2001) 7(8):2237-2245.
   PubMed Web of Science ®Google Scholar